- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Taysha Gene Therapies Inc (TSHA)

- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: TSHA (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $10.57
1 Year Target Price $10.57
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -74.45% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.38B USD | Price to earnings Ratio - | 1Y Target Price 10.57 |
Price to earnings Ratio - | 1Y Target Price 10.57 | ||
Volume (30-day avg) 10 | Beta 1.04 | 52 Weeks Range 1.05 - 5.51 | Updated Date 12/7/2025 |
52 Weeks Range 1.05 - 5.51 | Updated Date 12/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.33 |
Earnings Date
Report Date 2025-11-13 | When Before Market | Estimate -0.08 | Actual -0.0875 |
Profitability
Profit Margin - | Operating Margin (TTM) -1618.54% |
Management Effectiveness
Return on Assets (TTM) -25.7% | Return on Equity (TTM) -64.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1154974833 | Price to Sales(TTM) 219.22 |
Enterprise Value 1154974833 | Price to Sales(TTM) 219.22 | ||
Enterprise Value to Revenue 183.04 | Enterprise Value to EBITDA -0.61 | Shares Outstanding 273919373 | Shares Floating 175218005 |
Shares Outstanding 273919373 | Shares Floating 175218005 | ||
Percent Insiders 11.04 | Percent Institutions 97 |
Upturn AI SWOT
Taysha Gene Therapies Inc

Company Overview
History and Background
Taysha Gene Therapies, Inc. was founded in 2020 to focus on developing and commercializing gene therapies for monogenic diseases of the central nervous system. It has grown rapidly through licensing agreements and internal development programs.
Core Business Areas
- Gene Therapy Development: Developing AAV-based gene therapies for rare and monogenic CNS diseases.
- Licensing and Partnerships: Acquiring rights to promising gene therapy programs from academic institutions and other companies.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its gene therapy candidates.
Leadership and Structure
RA Session II is the President, CEO and Founder. The organizational structure is typical of a biotech company, with departments focusing on research, development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- TSHA-101: Gene therapy for GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases). Market share is currently 0% as it's in clinical development. Competitors include traditional supportive care methods and potential future gene therapies from other companies. No current alternatives exist in the market.
- TSHA-102: Gene therapy for Rett syndrome. Market share is currently 0% as it's in clinical development. Competitors include symptom management therapies and potential future gene therapies. No current alternatives exist in the market.
- TSHA-120: Gene therapy for Giant axonal neuropathy (GAN). Market share is currently 0% as it's in clinical development. Competitors include supportive care and clinical trials for other potential GAN therapies. No current alternatives exist in the market.
Market Dynamics
Industry Overview
The gene therapy industry is rapidly growing, driven by advancements in AAV vector technology and increasing regulatory approvals. High unmet medical needs in rare diseases fuel demand.
Positioning
Taysha is a clinical-stage company focused on CNS gene therapies, with a portfolio of promising candidates targeting rare diseases. Its competitive advantage lies in its experienced management team and exclusive licenses to key technologies.
Total Addressable Market (TAM)
The TAM for gene therapies targeting CNS disorders is estimated to be in the billions of dollars. Taysha is positioned to capture a significant share of this market if its therapies are approved.
Upturn SWOT Analysis
Strengths
- Strong pipeline of gene therapy candidates
- Experienced management team
- Exclusive licenses to key technologies
- Focus on rare and monogenic CNS diseases
Weaknesses
- High cash burn rate
- Dependence on clinical trial success
- Limited commercialization experience
- Potential regulatory hurdles
Opportunities
- Expansion of pipeline through licensing and acquisitions
- Partnerships with larger pharmaceutical companies
- Accelerated regulatory pathways for rare diseases
- Advancements in gene therapy technology
Threats
- Clinical trial failures
- Regulatory delays or rejections
- Competition from other gene therapy companies
- High cost of gene therapies and reimbursement challenges
Competitors and Market Share
Key Competitors
- AVXS
- CRIS
- BLUE
Competitive Landscape
Taysha faces competition from established gene therapy companies with approved products and larger pipelines. Its success depends on differentiating its therapies through improved efficacy, safety, or target patient populations.
Growth Trajectory and Initiatives
Historical Growth: Taysha's historical growth is characterized by the expansion of its pipeline through licensing deals and advancement of its clinical programs.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals of its gene therapy candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing TSHA-101 and TSHA-102 into later-stage clinical trials, and strengthening its manufacturing capabilities.
Summary
Taysha Gene Therapies is a high-risk, high-reward investment. Its strength lies in its promising pipeline of gene therapies for rare CNS diseases. However, it faces significant challenges related to clinical trial success, regulatory approvals, and commercialization. Positive clinical trial data and successful regulatory filings are critical for its future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Taysha Gene Therapies Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biotechnology companies carries significant risks, including clinical trial failures and regulatory setbacks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Taysha Gene Therapies Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2020-09-24 | CEO & Chairman Mr. Sean P. Nolan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 73 | Website https://www.tayshagtx.com |
Full time employees 73 | Website https://www.tayshagtx.com | ||
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
Home 

